

We're no longer capturing clinical outcomes through Audaire Health for select medical benefit drugs for commercial members

Currently, Blue Cross Blue Shield of Michigan and Blue Care Network request that providers submit clinical outcomes using the Audaire Health provider portal following the approval of prior authorization requests for and administration of certain high-cost medical benefit drugs for Blue Cross and BCN commercial members.

Starting Jan. 1, 2026:

- You'll no longer need to track clinical outcomes through the Audaire provider portal. As a result, you'll no longer receive email messages from Audaire prompting you to report outcomes for Blue Cross and BCN members.
- You'll no longer have access to the Audaire portal for Blue Cross and BCN members. If you attempt to recreate an Audaire portal account to report outcomes for a Blue Cross or BCN member, Audaire will redirect you to the Medical and Pharmacy Drug PA Portal.

Important: Health care providers must continue to submit prior authorization requests for the affected drugs (see below) through the Medical and Pharmacy Drug PA Portal.

Submit all prior authorization requests for affected drugs through the Medical and Pharmacy Drug PA Portal

To submit prior authorization requests for the affected drugs (see below) do this:

1. Log in to our provider portal (availability.com).
2. Click *Payer Spaces* on the menu bar and then click the BCBSM and BCN logo.
3. In the Applications tab, click the *Medical and Pharmacy Benefit Drug Prior Auth* tile.

Important: If you've been requesting the renewal of prior authorization requests for Spinraza® through the Audaire provider portal, you'll need to submit those requests through the Medical and Pharmacy Drug PA Portal starting Jan. 1.

Note: If you need to request access to our provider portal, see the [Register for Web Tools](#) webpage on **bcbsm.com**.

Some Blue Cross commercial groups aren't subject to these requirements

For Blue Cross commercial, this prior authorization requirement applies only to groups that participate in the standard commercial Medical Drug Prior Authorization Program for drugs administered under the medical benefit. To determine whether a group participates in the prior authorization program, see the [Specialty Pharmacy Prior Authorization Master Opt-in/out Group List](#).

Note: Blue Cross and Blue Shield Federal Employee Program® members and UAW Retiree Medical Benefits Trust (non-Medicare) members don't participate in the standard prior authorization program.

Drugs affected by this change

The following drugs are affected this change:

Drugs used for	Affected drugs
Spinal muscular atrophy (SMA)	<ul style="list-style-type: none"> Spinraza (nusinersen) Zolgensma® (onasemnogene abeparvovec-xioi)
Chimeric antigen receptor T-cell (CAR-T) and tumor-infiltrating lymphocyte (TIL) therapies for various cancers	<ul style="list-style-type: none"> Abecma® (idecabtagene vicleucel) Amtagvi® (lifileucel) Aucatzyl® (obecabtagene autoleucel) Breyanzi® (lisocabtagene maraleucel) Carvykti® (ciltacabtagene autoleucel) Kymriah® (tisagenlecleucel) Tecartus® (brexucabtagene autoleucel) Yescarta® (axicabtagene ciloleucel)

For additional information about prior authorizations for medical benefit drugs, see the Blue Cross and BCN Medical Benefit Drugs pages on [ereferrals.bcbcm.com](https://www.bcbcm.com/authorizations).

[Subscribe](#) to Provider Alerts Weekly, a weekly email with a list of links to the previous week's provider alerts.

Availity® is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal and electronic data interchange services.